Sienna biopharmaceuticals, inc. (SNNA)
Balance Sheet / Quarterly
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Dec'16
Assets
Current assets:
Cash and cash equivalents

11,332

49,207

57,169

48,526

63,975

74,887

60,013

74,467

88,601

-

9,091

Cash

-

-

-

-

-

-

-

-

-

31,719

-

Restricted cash

213

181

181

181

181

181

181

181

181

181

109

Prepaid expenses and other current assets

8,186

1,229

1,319

1,705

2,903

2,573

2,198

2,698

2,044

3,474

1,323

Total current assets

19,731

50,617

58,669

50,412

67,059

77,641

62,392

77,346

90,826

35,374

10,523

Property and equipment, net

180

237

275

311

345

371

397

432

368

298

291

Operating lease right-of-use asset

81

712

772

-

-

-

-

-

-

-

-

In-process research and development

23,500

45,172

44,591

45,594

46,112

46,501

48,956

47,597

46,938

45,388

41,863

Goodwill

-

10,887

10,747

10,989

11,114

11,207

11,799

11,472

11,313

10,939

9,698

Other assets

-

-

-

-

-

-

-

-

3

3

2

Total assets

43,492

107,625

115,054

107,306

124,630

135,720

123,544

136,847

149,448

92,002

62,377

Liabilities and stockholders' equity
Current liabilities:
Accounts payable

187

1,522

2,180

2,792

3,479

4,180

1,863

2,357

1,579

2,992

1,691

Accrued personnel costs

164

1,945

1,537

3,057

3,025

1,875

1,522

2,646

1,739

-

959

Other accrued personnel costs

-

-

-

-

-

-

-

-

-

1,145

-

Other accrued expenses

941

3,246

4,136

5,000

7,092

7,077

5,522

3,007

5,275

3,226

2,097

Contingent consideration, current portion

-

14,100

14,600

13,500

-

-

-

-

4,675

4,118

4,764

Early exercise liability, current portion

-

-

-

-

213

213

213

231

242

270

372

Total current liabilities

1,292

20,813

22,453

24,349

13,809

13,345

9,120

8,241

13,510

11,751

9,883

Contingent consideration—net of current portion

-

19,400

19,200

15,700

24,500

25,200

24,400

22,900

22,625

22,082

19,346

Operating lease liability—net of current portion

-

544

587

-

-

-

-

-

-

-

-

Early exercise liability-net of current portion

-

-

-

-

98

151

205

258

311

375

444

Success payment liability

-

-

-

-

688

881

2,119

3,285

5,794

3,335

1,262

Long-term debt, net

-

29,474

29,237

30,125

29,983

29,897

-

-

-

-

-

Deferred tax liability

5,358

10,406

10,272

10,503

10,622

10,712

11,277

10,964

10,812

10,455

9,325

Other long-term liabilities

-

5

19

48

-

-

-

-

-

-

-

Total liabilities not subject to compromise

6,650

-

-

80,725

-

-

-

-

-

-

-

Liabilities subject to compromise

13,741

-

-

-

-

-

-

-

-

-

-

Total liabilities

20,391

80,642

81,768

80,725

79,700

80,186

47,121

45,648

53,052

47,998

40,260

Commitments and contingencies (Note 9)

-

-

-

-

0

0

0

-

0

0

0

Stockholders' equity:
Preferred stock, $0.0001 par value, 10,000 shares authorized, no shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively

-

-

-

-

0

0

0

-

-

-

-

Common stock, $0.0001 par value, 300,000 shares authorized, 30,908 and 21,177 shares issued and 30,765 and 20,870 outstanding at September 30, 2019 and December 31, 2018, respectively

-

-

0

-

0

0

0

0

3

1

1

Additional paid-in capital

209,818

208,261

206,886

182,750

181,108

174,523

172,679

171,726

166,402

-553

-1,683

Accumulated other comprehensive income

1,303

2,772

2,186

3,199

3,855

4,250

6,744

5,370

4,699

3,111

-366

Accumulated deficit

-188,020

-184,050

-175,786

-159,368

-140,033

-123,239

-103,000

-85,897

-74,708

-58,318

-35,352

Total stockholders' equity

23,101

26,983

33,286

26,581

44,930

55,534

76,423

91,199

96,396

44,004

22,117

Total liabilities and stockholders' equity

43,492

107,625

115,054

107,306

124,630

135,720

123,544

136,847

149,448

92,002

62,377